Inhibition of L-arginine transport in platelets by asymmetric dimethylarginine and NG-monomethyl-L-arginine: Effects of arterial hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 10, 2004, Pages 738-740

  Brunini, T M C ^a   Moss, M B ^a   Siqueira, M A S ^a   Meirelles, L R ^a   Rozentul, A L ^a   Mann, G E ^b   Ellory, J C ^c   Soares De Moura, R ^a   Mendes Ribeiro, Antônio Cláudio ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arginine transport; Asymmetric dimethyl arginine; Hypertension; N G monomethyl L arginine; Platelets; System y+L

Indexed keywords

AMINOGUANIDINE; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; TRITIUM;

ADULT; AMINO ACID TRANSPORT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; PATHOPHYSIOLOGY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; ARGININE; ARTERIES; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD PLATELETS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; OOCYTES; P-CHLOROMERCURIBENZOIC ACID;

EID: 9144258437     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04067.x     Document Type: Article

References (21)

1. Moncada S, Palmer RMJ, Higgs A. Nitric oxide. Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
2. Vallance P. Nitric oxide: Therapeutic opportunities. Fundam. Clin. Phamacol. 2002; 17: 1-10.
3. Walford G, Loscalzo J. Nitric oxide in vascular biology. J. Thromb. Haemost. 2003; 1: 2112-18.
4. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 191-220.
5. G-monomethyl-L-arginine in end stage renal failure patients on regular haemodialysis. Exp. Physiol. 1996; 81: 475-81.
6. Leiper J, Vallance P. Biological significance of endogenous methyl-arginine that inhibits nitric oxide synthases. Cardiovasc. Res. 1999; 43: 542-8.
7. Mendes Ribeiro AC, Brunini TMC, Ellory CE, Mann GE. Abnormalities in L-arginine transport and NO biosynthesis in chronic renal and heart failure. Cardiovasc. Res. 2001; 49: 697-712.
8. Boger RH, Vallance P, Cooke JP. Assymetric dimethylarginine: A key regulator of nitric oxide synthase. Atheroscler. Suppl. 2003; 4: 1-3.
9. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 1990; 87: 5193-7.
10. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. Clin. Med. 1995; 125: 370-7.
11. Minuz P, Patrignani P, Gaino S et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
12. Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 41: 1-7.
13. Camilletti A, Moretti N, Giacchetti G et al. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am. J. Hypertens. 2001; 14: 382-6.
14. Mendes Ribeiro AC, Brunini TMC, Yaqoob M, Aronson JK. Identification of system y+L as the high affinity transporter for L-arginine in human platelets. Up-regulation of L-arginine influx in uraemia. Eur. J. Physiol. 1999; 438: 573-5.
15. +L. A canditate gene for lysinuric protein intolerance. J. Biol. Chem. 1998; 273: 32437-45.
16. Moss MB, Brunini TMC, Soares de Moura R et al. Diminished L-arginine bioavailability in hypertension. Clin. Sci. 2004 (in press).
17. Estevez R, Camps M, Rojas AM et al. The amino acid transport system y+L/4F2hc is a heteromultimeric complex. FASEB J. 1998; 12: 1319-29.
18. Chen LY, Mehta JL. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J. Pharmacol. Exp. Ther. 1996; 276: 252-7.
19. Cendan JC, Topping DL, Pruitt J, Snowdy S, Copeland EM, Lin DS. Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide production in a murine breast cancer cell line. J. Surg. Res. 1996; 60: 284-8.
20. Hwang TL, Yang JT, Lau YT. Arginine-nitric oxide pathway in plasma membrane of rat hepatocytes during early and late sepsis. Crit. Care Med. 1999; 27: 137-41.
21. +L. Pflügers Arch. 2003; 445: 540-6.